Biologics MD

BiologicsMD is a preclinical-stage biotechnology company founded in 2010, developing targeted therapies for hair loss, bone disorders, and oncology. The company's core technology involves creating recombinant fusion proteins that have two functional parts: a binding domain that targets Type I collagen in skin and bone, and an active domain that stimulates therapeutic effects at the disease site. This approach is designed to deliver treatment directly where it's needed, allowing for infrequent dosing—as seldom as every one to six months—and minimizing off-target effects.

The company's primary focus is on its portfolio of hair cycle stimulators (HCS) for various forms of alopecia, including alopecia areata, androgenetic alopecia, and chemotherapy-induced hair loss. Its lead candidate, BMD-1141, is a fusion protein that combines a parathyroid hormone (PTH) agonist with a collagen-binding domain to stimulate hair follicles. In addition to hair loss, BiologicsMD has programs targeting bone disorders, such as developing a bone graft substitute for spinal fusion and treatments for bone metastases in cancer. The company's business model is centered on advancing its pipeline through early clinical trials before seeking a strategic acquisition or licensing deal with a major pharmaceutical firm.

The management team includes President & CEO J. David Owens, who has over 35 years of experience in the pharmaceutical and biotech industries, including roles at Genentech, Merck, and King Pharmaceuticals. Dr. Robyn Goforth serves as Chief Scientific Officer, bringing over 15 years of experience in protein design and production. Dr. Robert Gensure, a co-inventor of the core technology and a pediatric endocrinologist at Tufts Medical Center, is the Chief Medical Officer.

Keywords: fusion proteins, targeted drug delivery, alopecia treatment, bone disorders, hair cycle stimulators, collagen-binding domain, parathyroid hormone receptor, preclinical therapeutics, recombinant proteins, androgenetic alopecia, chemotherapy-induced alopecia, alopecia areata, bone repair, oncology, drug development, biotechnology